{"id":60234,"date":"2024-10-25T13:04:19","date_gmt":"2024-10-25T11:04:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/"},"modified":"2024-10-25T13:04:19","modified_gmt":"2024-10-25T11:04:19","slug":"egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/","title":{"rendered":"Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4\/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting"},"content":{"rendered":"
\n

PARIS–(BUSINESS WIRE)–Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will present at the Society for Immunotherapy of Cancer Meeting taking place in Houston, Texas from November 6th<\/sup> to 10th<\/sup>, 2024.\n<\/p>\n

\nThe presentation, entitled \u201cPreferential tumor retention of EGL-001, a CTLA-4\/CD25 antagonist fusion protein, to selectively deplete tumor Tregs and minimize peripheral toxicities: towards a first-in-human clinical study<\/i>\u201d, will highlight the development and promising preclinical results of EGL-001, a humanized antibody designed to selectively target regulatory T cells (Tregs) within the tumor microenvironment. The data showcases EGL-001’s potential as single-agent and to enhance the effectiveness of immune checkpoint blockade therapies by depleting tumor-associated Tregs, leading to increased CD8+ T cell activation and anti-tumor responses in preclinical models.\n<\/p>\n

\nThe SITC presentation will include key findings from studies in mouse models and cynomolgus monkeys, demonstrating the safety, tolerability, and efficacy of EGL-001, as well as its preferential tumor accumulation and rapid clearance from peripheral organs. These promising results leading Egle Therapeutics to conduct a first-in-human open-label, phase I\/II trial evaluating the safety, tolerability, PK and preliminary activity of EGL-001 in patients with selected solid tumors, with the goal to address the critical need for more effective immunotherapies in cancer treatment.\n<\/p>\n

\nSession Date<\/b> Saturday, Nov. 9 ; Location<\/b>: George R. Brown Convention Center – Level 1 – Exhibit Halls AB ; Poster Board Number<\/b>: 674\n<\/p>\n

\nAbout Egle Therapeutics SAS (Egle)<\/b>\n<\/p>\n

\nEgle Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle is evaluating its most advanced drug candidate in oncology, EGL-001 (a Treg-selective anti-CTLA4-IL-2m), in a Phase I\/II clinical trial. In auto-immunity, Egle aspires to advance toward the clinic its most advanced drug candidate, EGL-003 (non-targeted IL-2 Treg engager), currently in IND-enabling studies.\n<\/p>\n

\nFind out more at www.egle-tx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\ncontact@egle-tx.com<\/a> \/ 0033 (0)1 86 64 08 57
\n
investor.relations@egle-tx.com<\/a> \/ 0033 (0)1 86 64 08 57\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PARIS–(BUSINESS WIRE)–Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will present at the Society for Immunotherapy of Cancer Meeting taking place in Houston, Texas from November 6th to 10th, 2024. The presentation, entitled \u201cPreferential tumor retention of EGL-001, a CTLA-4\/CD25 antagonist fusion protein, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60234","6":"format-standard","7":"category-industry"},"yoast_head":"\nEgle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4\/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4\/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PARIS–(BUSINESS WIRE)–Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will present at the Society for Immunotherapy of Cancer Meeting taking place in Houston, Texas from November 6th to 10th, 2024. The presentation, entitled \u201cPreferential tumor retention of EGL-001, a CTLA-4\/CD25 antagonist fusion protein, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-25T11:04:19+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4\\\/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting\",\"datePublished\":\"2024-10-25T11:04:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\\\/\"},\"wordCount\":362,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\\\/\",\"name\":\"Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4\\\/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2024-10-25T11:04:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4\\\/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4\/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4\/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting - Pharma Trend","og_description":"PARIS–(BUSINESS WIRE)–Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will present at the Society for Immunotherapy of Cancer Meeting taking place in Houston, Texas from November 6th to 10th, 2024. The presentation, entitled \u201cPreferential tumor retention of EGL-001, a CTLA-4\/CD25 antagonist fusion protein, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2024-10-25T11:04:19+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4\/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting","datePublished":"2024-10-25T11:04:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/"},"wordCount":362,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/","url":"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/","name":"Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4\/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2024-10-25T11:04:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/egle-therapeutics-to-share-preclinical-efficacy-data-for-egl-001-a-ctla-4-cd25-antagonist-fusion-protein-at-the-society-for-immunotherapy-of-cancer-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4\/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60234"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60234\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}